Besides primary and acquired resistance to immunotherapy, it was recently reported that PD-1/PD-L1 blockade might develop “hyperprogressive disease” in some patients, which means accelerated tumor growth after anti-PD-1/PD-L1 inhibitors [135]. This evidence concerns the gene PDCD1 and neoplasm.